Monogenic Diabetes in the Progress for Diabetes Genetics in Youth (ProDiGY) Collaboration

Monogenic diabetes, including maturity-onset diabetes of the young (MODY), is frequently misdiagnosed as type 1 or type 2 diabetes. Correct diagnosis can result in a change in clinical treatment and impacts prediction of complications and familial risk. Clinical algorithms can select individuals for...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2018-07, Vol.67 (Supplement_1)
Hauptverfasser: TODD, JENNIFER, KLEINBERGER, JEFFREY W., SRINIVASAN, SHYLAJA, TOLLEFSEN, SHERIDA E., LEVITSKY, LYNNE L., KATZ, LORRAINE E.L., TRYGGESTAD, JEANIE B., BACHA, FIDA, IMPERATORE, GIUSEPPINA, LAWRENCE, JEAN M., PIHOKER, CATHERINE, DIVERS, JASMIN, FLANNICK, JASON, DABELEA, DANA, FLOREZ, JOSE C., POLLIN, TONI I.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_1
container_start_page
container_title Diabetes (New York, N.Y.)
container_volume 67
creator TODD, JENNIFER
KLEINBERGER, JEFFREY W.
SRINIVASAN, SHYLAJA
TOLLEFSEN, SHERIDA E.
LEVITSKY, LYNNE L.
KATZ, LORRAINE E.L.
TRYGGESTAD, JEANIE B.
BACHA, FIDA
IMPERATORE, GIUSEPPINA
LAWRENCE, JEAN M.
PIHOKER, CATHERINE
DIVERS, JASMIN
FLANNICK, JASON
DABELEA, DANA
FLOREZ, JOSE C.
POLLIN, TONI I.
description Monogenic diabetes, including maturity-onset diabetes of the young (MODY), is frequently misdiagnosed as type 1 or type 2 diabetes. Correct diagnosis can result in a change in clinical treatment and impacts prediction of complications and familial risk. Clinical algorithms can select individuals for genetic testing; however, up to half of youth with MODY do not meet clinical criteria. Other barriers also limit access to genetic testing. To assess the prevalence of MODY in youth with a clinical diagnosis of type 2 diabetes, we evaluated whole-exome sequence data from ProDiGY, a collaboration of the TODAY, SEARCH for Diabetes in Youth, and T2D-GENES studies. Focusing on 14 genes previously identified as causal for MODY (HNF4A, GCK, HNF1A, PDX1, HNF1B, NEUROD1, KLF11, CEL, PAX4, INS, BLK, KCNJ11, ABCC8, and APPL1) we considered patients to have MODY if they carried one or more variants classified as likely pathogenic (LP) or pathogenic (P) according to current guidelines. We found 77 of 3650 patients carried an LP/P variant in HNF4A (14 individuals), GCK (22), HNF1A (32), PDX1 (4), INS (3), and PAX4 (2). Compared to those with no LP/P variants, youth with MODY had a younger age at diagnosis (12.9 ± 0.3 vs. 13.6 ± 0.1, P=0.01) and lower fasting C-peptide levels (3.0 ± 0.2 vs. 4.5 ± 0.1, P=0.0001), although for both measures, the range of values overlapped between the two groups. Youth with MODY were less likely to have hypertension (6.9% vs. 18.2%, P=0.03) and less likely to be on insulin (32.0% vs. 51.1%, P=0.001). Parental history of diabetes was not significantly different. MODY was found in all race/ethnic groups. Using a comprehensive set of MODY genes, we identified MODY in 2% of youth with clinically diagnosed type 2 diabetes; in 88% (n=68) the specific diagnosis would direct management. While these individuals differed significantly on several clinical characteristics, no criterion reliably separated the two groups. Further study is needed to find ideal criteria to select individuals for genetic testing.
doi_str_mv 10.2337/db18-268-OR
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_2337_db18_268_OR</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_2337_db18_268_OR</sourcerecordid><originalsourceid>FETCH-LOGICAL-c78R-fb65ca9ee2f9765d08769beada754cf4a452b9b7d688095b108eed8fe20444f13</originalsourceid><addsrcrecordid>eNpFkM1KxDAYRYMoWEdXvkCWikST9CfJUjrjKIxUyizsqiTtl5lIbSSpC9_ejgpyF3dxD3dxELpk9JanqbjrDZOEF5JU9RFKmEoVSbl4PUYJpYwTJpQ4RWcxvlFKizkJap796Hcwug4vnTYwQcRuxNMe8EvwuwAxYuvD_7iGESbX_VCN_5z2-GoGl27dXOPSD4M2PujJ-fEcnVg9RLj46wXaPqy25SPZVOun8n5DOiFrYk2Rd1oBcKtEkfdUikIZ0L0WedbZTGc5N8qIvpCSqtwwKgF6aYHTLMssSxfo5ve2Cz7GALb9CO5dh6-W0fYgpT1IaWcpbVWn30TpVbM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Monogenic Diabetes in the Progress for Diabetes Genetics in Youth (ProDiGY) Collaboration</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>TODD, JENNIFER ; KLEINBERGER, JEFFREY W. ; SRINIVASAN, SHYLAJA ; TOLLEFSEN, SHERIDA E. ; LEVITSKY, LYNNE L. ; KATZ, LORRAINE E.L. ; TRYGGESTAD, JEANIE B. ; BACHA, FIDA ; IMPERATORE, GIUSEPPINA ; LAWRENCE, JEAN M. ; PIHOKER, CATHERINE ; DIVERS, JASMIN ; FLANNICK, JASON ; DABELEA, DANA ; FLOREZ, JOSE C. ; POLLIN, TONI I.</creator><creatorcontrib>TODD, JENNIFER ; KLEINBERGER, JEFFREY W. ; SRINIVASAN, SHYLAJA ; TOLLEFSEN, SHERIDA E. ; LEVITSKY, LYNNE L. ; KATZ, LORRAINE E.L. ; TRYGGESTAD, JEANIE B. ; BACHA, FIDA ; IMPERATORE, GIUSEPPINA ; LAWRENCE, JEAN M. ; PIHOKER, CATHERINE ; DIVERS, JASMIN ; FLANNICK, JASON ; DABELEA, DANA ; FLOREZ, JOSE C. ; POLLIN, TONI I.</creatorcontrib><description>Monogenic diabetes, including maturity-onset diabetes of the young (MODY), is frequently misdiagnosed as type 1 or type 2 diabetes. Correct diagnosis can result in a change in clinical treatment and impacts prediction of complications and familial risk. Clinical algorithms can select individuals for genetic testing; however, up to half of youth with MODY do not meet clinical criteria. Other barriers also limit access to genetic testing. To assess the prevalence of MODY in youth with a clinical diagnosis of type 2 diabetes, we evaluated whole-exome sequence data from ProDiGY, a collaboration of the TODAY, SEARCH for Diabetes in Youth, and T2D-GENES studies. Focusing on 14 genes previously identified as causal for MODY (HNF4A, GCK, HNF1A, PDX1, HNF1B, NEUROD1, KLF11, CEL, PAX4, INS, BLK, KCNJ11, ABCC8, and APPL1) we considered patients to have MODY if they carried one or more variants classified as likely pathogenic (LP) or pathogenic (P) according to current guidelines. We found 77 of 3650 patients carried an LP/P variant in HNF4A (14 individuals), GCK (22), HNF1A (32), PDX1 (4), INS (3), and PAX4 (2). Compared to those with no LP/P variants, youth with MODY had a younger age at diagnosis (12.9 ± 0.3 vs. 13.6 ± 0.1, P=0.01) and lower fasting C-peptide levels (3.0 ± 0.2 vs. 4.5 ± 0.1, P=0.0001), although for both measures, the range of values overlapped between the two groups. Youth with MODY were less likely to have hypertension (6.9% vs. 18.2%, P=0.03) and less likely to be on insulin (32.0% vs. 51.1%, P=0.001). Parental history of diabetes was not significantly different. MODY was found in all race/ethnic groups. Using a comprehensive set of MODY genes, we identified MODY in 2% of youth with clinically diagnosed type 2 diabetes; in 88% (n=68) the specific diagnosis would direct management. While these individuals differed significantly on several clinical characteristics, no criterion reliably separated the two groups. Further study is needed to find ideal criteria to select individuals for genetic testing.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db18-268-OR</identifier><language>eng</language><ispartof>Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c78R-fb65ca9ee2f9765d08769beada754cf4a452b9b7d688095b108eed8fe20444f13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>TODD, JENNIFER</creatorcontrib><creatorcontrib>KLEINBERGER, JEFFREY W.</creatorcontrib><creatorcontrib>SRINIVASAN, SHYLAJA</creatorcontrib><creatorcontrib>TOLLEFSEN, SHERIDA E.</creatorcontrib><creatorcontrib>LEVITSKY, LYNNE L.</creatorcontrib><creatorcontrib>KATZ, LORRAINE E.L.</creatorcontrib><creatorcontrib>TRYGGESTAD, JEANIE B.</creatorcontrib><creatorcontrib>BACHA, FIDA</creatorcontrib><creatorcontrib>IMPERATORE, GIUSEPPINA</creatorcontrib><creatorcontrib>LAWRENCE, JEAN M.</creatorcontrib><creatorcontrib>PIHOKER, CATHERINE</creatorcontrib><creatorcontrib>DIVERS, JASMIN</creatorcontrib><creatorcontrib>FLANNICK, JASON</creatorcontrib><creatorcontrib>DABELEA, DANA</creatorcontrib><creatorcontrib>FLOREZ, JOSE C.</creatorcontrib><creatorcontrib>POLLIN, TONI I.</creatorcontrib><title>Monogenic Diabetes in the Progress for Diabetes Genetics in Youth (ProDiGY) Collaboration</title><title>Diabetes (New York, N.Y.)</title><description>Monogenic diabetes, including maturity-onset diabetes of the young (MODY), is frequently misdiagnosed as type 1 or type 2 diabetes. Correct diagnosis can result in a change in clinical treatment and impacts prediction of complications and familial risk. Clinical algorithms can select individuals for genetic testing; however, up to half of youth with MODY do not meet clinical criteria. Other barriers also limit access to genetic testing. To assess the prevalence of MODY in youth with a clinical diagnosis of type 2 diabetes, we evaluated whole-exome sequence data from ProDiGY, a collaboration of the TODAY, SEARCH for Diabetes in Youth, and T2D-GENES studies. Focusing on 14 genes previously identified as causal for MODY (HNF4A, GCK, HNF1A, PDX1, HNF1B, NEUROD1, KLF11, CEL, PAX4, INS, BLK, KCNJ11, ABCC8, and APPL1) we considered patients to have MODY if they carried one or more variants classified as likely pathogenic (LP) or pathogenic (P) according to current guidelines. We found 77 of 3650 patients carried an LP/P variant in HNF4A (14 individuals), GCK (22), HNF1A (32), PDX1 (4), INS (3), and PAX4 (2). Compared to those with no LP/P variants, youth with MODY had a younger age at diagnosis (12.9 ± 0.3 vs. 13.6 ± 0.1, P=0.01) and lower fasting C-peptide levels (3.0 ± 0.2 vs. 4.5 ± 0.1, P=0.0001), although for both measures, the range of values overlapped between the two groups. Youth with MODY were less likely to have hypertension (6.9% vs. 18.2%, P=0.03) and less likely to be on insulin (32.0% vs. 51.1%, P=0.001). Parental history of diabetes was not significantly different. MODY was found in all race/ethnic groups. Using a comprehensive set of MODY genes, we identified MODY in 2% of youth with clinically diagnosed type 2 diabetes; in 88% (n=68) the specific diagnosis would direct management. While these individuals differed significantly on several clinical characteristics, no criterion reliably separated the two groups. Further study is needed to find ideal criteria to select individuals for genetic testing.</description><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpFkM1KxDAYRYMoWEdXvkCWikST9CfJUjrjKIxUyizsqiTtl5lIbSSpC9_ejgpyF3dxD3dxELpk9JanqbjrDZOEF5JU9RFKmEoVSbl4PUYJpYwTJpQ4RWcxvlFKizkJap796Hcwug4vnTYwQcRuxNMe8EvwuwAxYuvD_7iGESbX_VCN_5z2-GoGl27dXOPSD4M2PujJ-fEcnVg9RLj46wXaPqy25SPZVOun8n5DOiFrYk2Rd1oBcKtEkfdUikIZ0L0WedbZTGc5N8qIvpCSqtwwKgF6aYHTLMssSxfo5ve2Cz7GALb9CO5dh6-W0fYgpT1IaWcpbVWn30TpVbM</recordid><startdate>20180701</startdate><enddate>20180701</enddate><creator>TODD, JENNIFER</creator><creator>KLEINBERGER, JEFFREY W.</creator><creator>SRINIVASAN, SHYLAJA</creator><creator>TOLLEFSEN, SHERIDA E.</creator><creator>LEVITSKY, LYNNE L.</creator><creator>KATZ, LORRAINE E.L.</creator><creator>TRYGGESTAD, JEANIE B.</creator><creator>BACHA, FIDA</creator><creator>IMPERATORE, GIUSEPPINA</creator><creator>LAWRENCE, JEAN M.</creator><creator>PIHOKER, CATHERINE</creator><creator>DIVERS, JASMIN</creator><creator>FLANNICK, JASON</creator><creator>DABELEA, DANA</creator><creator>FLOREZ, JOSE C.</creator><creator>POLLIN, TONI I.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20180701</creationdate><title>Monogenic Diabetes in the Progress for Diabetes Genetics in Youth (ProDiGY) Collaboration</title><author>TODD, JENNIFER ; KLEINBERGER, JEFFREY W. ; SRINIVASAN, SHYLAJA ; TOLLEFSEN, SHERIDA E. ; LEVITSKY, LYNNE L. ; KATZ, LORRAINE E.L. ; TRYGGESTAD, JEANIE B. ; BACHA, FIDA ; IMPERATORE, GIUSEPPINA ; LAWRENCE, JEAN M. ; PIHOKER, CATHERINE ; DIVERS, JASMIN ; FLANNICK, JASON ; DABELEA, DANA ; FLOREZ, JOSE C. ; POLLIN, TONI I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c78R-fb65ca9ee2f9765d08769beada754cf4a452b9b7d688095b108eed8fe20444f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>TODD, JENNIFER</creatorcontrib><creatorcontrib>KLEINBERGER, JEFFREY W.</creatorcontrib><creatorcontrib>SRINIVASAN, SHYLAJA</creatorcontrib><creatorcontrib>TOLLEFSEN, SHERIDA E.</creatorcontrib><creatorcontrib>LEVITSKY, LYNNE L.</creatorcontrib><creatorcontrib>KATZ, LORRAINE E.L.</creatorcontrib><creatorcontrib>TRYGGESTAD, JEANIE B.</creatorcontrib><creatorcontrib>BACHA, FIDA</creatorcontrib><creatorcontrib>IMPERATORE, GIUSEPPINA</creatorcontrib><creatorcontrib>LAWRENCE, JEAN M.</creatorcontrib><creatorcontrib>PIHOKER, CATHERINE</creatorcontrib><creatorcontrib>DIVERS, JASMIN</creatorcontrib><creatorcontrib>FLANNICK, JASON</creatorcontrib><creatorcontrib>DABELEA, DANA</creatorcontrib><creatorcontrib>FLOREZ, JOSE C.</creatorcontrib><creatorcontrib>POLLIN, TONI I.</creatorcontrib><collection>CrossRef</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>TODD, JENNIFER</au><au>KLEINBERGER, JEFFREY W.</au><au>SRINIVASAN, SHYLAJA</au><au>TOLLEFSEN, SHERIDA E.</au><au>LEVITSKY, LYNNE L.</au><au>KATZ, LORRAINE E.L.</au><au>TRYGGESTAD, JEANIE B.</au><au>BACHA, FIDA</au><au>IMPERATORE, GIUSEPPINA</au><au>LAWRENCE, JEAN M.</au><au>PIHOKER, CATHERINE</au><au>DIVERS, JASMIN</au><au>FLANNICK, JASON</au><au>DABELEA, DANA</au><au>FLOREZ, JOSE C.</au><au>POLLIN, TONI I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Monogenic Diabetes in the Progress for Diabetes Genetics in Youth (ProDiGY) Collaboration</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2018-07-01</date><risdate>2018</risdate><volume>67</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Monogenic diabetes, including maturity-onset diabetes of the young (MODY), is frequently misdiagnosed as type 1 or type 2 diabetes. Correct diagnosis can result in a change in clinical treatment and impacts prediction of complications and familial risk. Clinical algorithms can select individuals for genetic testing; however, up to half of youth with MODY do not meet clinical criteria. Other barriers also limit access to genetic testing. To assess the prevalence of MODY in youth with a clinical diagnosis of type 2 diabetes, we evaluated whole-exome sequence data from ProDiGY, a collaboration of the TODAY, SEARCH for Diabetes in Youth, and T2D-GENES studies. Focusing on 14 genes previously identified as causal for MODY (HNF4A, GCK, HNF1A, PDX1, HNF1B, NEUROD1, KLF11, CEL, PAX4, INS, BLK, KCNJ11, ABCC8, and APPL1) we considered patients to have MODY if they carried one or more variants classified as likely pathogenic (LP) or pathogenic (P) according to current guidelines. We found 77 of 3650 patients carried an LP/P variant in HNF4A (14 individuals), GCK (22), HNF1A (32), PDX1 (4), INS (3), and PAX4 (2). Compared to those with no LP/P variants, youth with MODY had a younger age at diagnosis (12.9 ± 0.3 vs. 13.6 ± 0.1, P=0.01) and lower fasting C-peptide levels (3.0 ± 0.2 vs. 4.5 ± 0.1, P=0.0001), although for both measures, the range of values overlapped between the two groups. Youth with MODY were less likely to have hypertension (6.9% vs. 18.2%, P=0.03) and less likely to be on insulin (32.0% vs. 51.1%, P=0.001). Parental history of diabetes was not significantly different. MODY was found in all race/ethnic groups. Using a comprehensive set of MODY genes, we identified MODY in 2% of youth with clinically diagnosed type 2 diabetes; in 88% (n=68) the specific diagnosis would direct management. While these individuals differed significantly on several clinical characteristics, no criterion reliably separated the two groups. Further study is needed to find ideal criteria to select individuals for genetic testing.</abstract><doi>10.2337/db18-268-OR</doi></addata></record>
fulltext fulltext
identifier ISSN: 0012-1797
ispartof Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)
issn 0012-1797
1939-327X
language eng
recordid cdi_crossref_primary_10_2337_db18_268_OR
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
title Monogenic Diabetes in the Progress for Diabetes Genetics in Youth (ProDiGY) Collaboration
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T20%3A34%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Monogenic%20Diabetes%20in%20the%20Progress%20for%20Diabetes%20Genetics%20in%20Youth%20(ProDiGY)%20Collaboration&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=TODD,%20JENNIFER&rft.date=2018-07-01&rft.volume=67&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db18-268-OR&rft_dat=%3Ccrossref%3E10_2337_db18_268_OR%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true